Skip to content

Released Aug 10, 2020, before the open

10-Q filed Aug 10, 2020, 41 days after period end · 0001104659-20-092375

Q2 2020 · 10-Q
Revenue$10.97M−10.5% vs Q2 2019−49.3% vs Q1 2020
Net Income-$4.15MN/M vs Q2 2019N/M vs Q1 2020
EPS Diluted-$0.13N/M vs Q2 2019N/M vs Q1 2020
Operating Income-$2,240,000N/M
Operating Cash Flowderived-$7,835,000N/M
Free Cash Flowderived-$8,047,000N/M
Margins · derived
Operating margin-20.4%+27.3 pt vs Q2 2019
Net margin-37.8%+25.4 pt vs Q2 2019

What the release said

The release

Same quarter

MetricQ2 2020Q2 2019Q2 2018Q2 2017
Revenue$10.97M$12.25M$2.01M$6.36M
Net Income-$4.15M-$7.74M-$8.46M$450.00K
EPS Diluted-$0.13-$0.52-$0.06-$0.06

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Protalix BioTherapeutics, Inc. · CIK 1006281 · Engraved from SEC EDGAR